TBIO Translate Bio Inc

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

$17.26  +0.37 (2.16%)
As of 04/09/2021 15:59:46 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2018
Outstanding shares:  75,211,832
Average volume:  1,738,405
Market cap:   $1,298,156,220
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    89374L104
ISIN:        US89374L1044
Sedol:      BG88WT0
Valuation   (See tab for details)
PE ratio:   -24.14
PB ratio:   3.63
PS ratio:   9.35
Return on equity:   -15.08%
Net income %:   -38.75%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy